These vision problems are caused by non-arteritic ischemic optic neuropathy (NAION)
(2026, Jan 21)
Have a BRAT-plus-protein plan ready before you need it
7 Long-acting liraglutide was approved in 2009 and 2010 by the European Medicines Agency and FDA, respectively, followed by lixisenatide (2013 EMA, 2016 FDA), albiglutide (2014 for both EMA and FDA) and dulaglutide (2014 for both EMA and FDA) 8 On December 5, 2017, semaglutide was approved in the USA for its use as subcutaneous injection, while in Europe, semaglutide was approved by the EMA on February 8, 2018
With trials of potential long-term benefits of these medications still ongoing, the jury is out on whether their potential benefit justifies the cost
Mistake 6: drawing from a cold vial Tirzepatide is stored in the refrigerator